HaloLife Group was established in 2012 and is headquartered in Xiamen, China. The group owns two core subsidiaries: Xiamen Halosyntech Co., Ltd. and Halo Life (Xiamen) Technology Co., Ltd. It has branches in Hong Kong, Dubai, and Oman, and a wholly-owned subsidiary in Algeria, forming a global business network covering key domestic regions and important overseas markets.

The company conducts in-depth research and innovation in key areas such as antiviral, oncology, cardiovascular, and immunosuppressive fields. Products cover chemical small-molecule drug API and formulations, peptides, small nucleic acid products, and biologic drugs (including monoclonal antibodies, bispecific antibodies, and ADC drugs)

Halo Life has an efficient and experienced R&D and production team, supported by a cGMP production quality system aligned with international standards. The company possesses global commercialization capabilities, with markets covering China, the United States, Europe, the Middle East, Africa, and other countries or regions along the “Belt and Road” initiative. The company provides a full industry chain product supply, from key intermediates to active pharmaceutical ingredients (APIs) and formulations, as well as comprehensive support services covering factory construction, technology transfer, and product sales.

Halolife is dedicated to building a high-tech pharmaceutical enterprise that integrates engineering, technology, and product services with international competitiveness, aiming to become the most trusted partner for pharmaceutical companies worldwide.